CLINICAL_TRIALS ClinicalTrials.gov record update

Phase II Window Study of Pembrolizumab in Untreated B-Cell Non-Hodgkin Lymphoproliferative Diseases

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT03498612
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-25T22:28:59.088841+00:00
Published At: 2022-12-30T00:00:00+00:00
Record Updated At: 2025-11-12
Results Posted At: 2022-12-30
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Follicular Lymphoma", "Indolent B-Cell Non-Hodgkin Lymphoma", "Marginal Zone Lymphoma"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2025-11-12"
protocolSection.identificationModule.nctId: "NCT03498612"
protocolSection.identificationModule.officialTitle: "Phase II Window Study of Pembrolizumab in Untreated B-Cell Non-Hodgkin Lymphoproliferative Diseases"
protocolSection.statusModule.overallStatus: "TERMINATED"
protocolSection.designModule.phases: ["PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: "2022-12-30"

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.